HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

PNEUMONIA IN COPD PATIENTS RECEIVING INHALED GLUCOCORTICOSTEROIDS

Download full text PDF
Issue: 
2
Year: 
2017

Professor A. Vizel, MD; I. Vizel, Candidate of Medical Sciences; E. Gizatullina, Candidate of Medical Sciences Kazan State Medical University

The review evaluates the safety of using inhaled glucocorticosteroids and their combinations with long-acting β2-adrenomimetics for chronic obstructive pulmonary disease.

Keywords: 
pulmonology
chronic obstructive pulmonary disease
pneumonia
inhaled glucocorticosteroids



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Barnes P. Corticosteroid effects on cell signaling // Eur. Respir. J. – 2006; 27 (2): 413–26.
  2. Crim C., Pierre L., Daley-Yates P. A review of the pharmacology and pharmacokinetics of inhaled adults with asthma // Cochrane Database Syst. Rev. – 2000; CD001117.
  3. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2016. Available at: http://www.ginasthma.org/
  4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://www.goldcopd.org/
  5. Sibila O., Anzueto A., Restrepo M.I. The paradoxical effect on pneumonia of chronic inhaled corticosteroids // Clin. Pulm. Med. – 2013; 20 (1): 1–14.
  6. Nannini L., Poole P., Milan S. et al. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease // Cochrane Database Syst Rev. – 2013; 11: CD003794.
  7. Kaplan A. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice // Int. J. Chron. Obstruct. Pulmon. Dis. – 2015; 10: 2535–48.
  8. Kruis A., Ställberg B., Jones R. et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study // PLoS One. – 2014; 9 (3): e90145.
  9. Niederseer D., Richter S., Neunhäuserer D. et al. Symptomatic chronic obstructive pulmonary disease in clinical trials and in a population-based study // Sleep Breath. – 2015; 19 (3): 801–8.
  10. Wilkie M., Finch S., Schembri S. Inhaled corticosteroids for chronic obstructive pulmonary disease – the shifting treatment paradigm // COPD. – 2015; 12 (5): 582–90.
  11. Price D., Miravitlles M., Pavord I. et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis // NPJ Prim. Care Respir. Med. – 2016; 26: 16061.
  12. Barabanova E.N., Kolontareva Ju.M. Ingaljatsionnye gljukokortikosteroidy / dlitel'no dejstvujuschie β2-agonisty v lechenii hronicheskoj obstruktivnoj bolezni legkih: diskussija prodolzhaetsja // Pul'monologija. – 2016; 26 (3): 357–63.
  13. Singanayagam A., Chalmers J., Hill A. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association // QJM. – 2010; 103 (6): 379–85.
  14. Calverley P., Anderson J., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease // N. Engl. J. Med. – 2007; 356 (8): 775–89.
  15. Ernst P., Gonzalez A., Brassard P. et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia // Am. J. Respir. Crit Care. Med. – 2007; 176 (2): 162–6.
  16. Ernst P., Suissa S. Pneumonia in elderly patients with chronic obstructive pulmonary disease // Curr. Infect. Dis. Rep. – 2008; 10 (3): 223–8.
  17. Bajmakanova G.E., Zubairova P.A., Avdeev S.N. i dr. Osobennosti klinicheskoj kartiny i techenija vnebol'nichnoj pnevmonii u patsientov s hronicheskoj obstruktivnoj bolezn'ju legkih // Pul'monologija. – 2009; 2: 33–41.
  18. Calverley P., Stockley R., Seemungal T. et al. Reported pneumonia in COPD: findings from the INSPIRE study // Chest. – 2011; 139 (3): 505–12.
  19. Yawn B., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis // Int. J. Chron. Obstruct. Pulmon. Dis. – 2013; 8: 295–304.
  20. Sibila O., Laserna E., Mortensen E. et al. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance // Respir. Care. – 2013; 58 (9): 1489–94.
  21. Wedzicha J., Singh D., Vestbo J. et al. Extrafine beclomethasone / formoterol in severe COPD patients with history of exacerbations // Respir. Med. – 2014; 108 (8): 1153–62.
  22. Crim C., Dransfield M., Bourbeau J. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD // Ann. Am. Thorac. Soc. – 2015; 12 (1): 27–34.
  23. Halpin D., Gray J., Edwards S. et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials // Int. J. Clin. Pract. – 2011; 65 (7): 764–74.
  24. Ruiz García V., Compte Torrero L. Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients // Med. Clin. (Barc). – 2011; 137 (7): 302–4.
  25. Janson C., Larsson K., Lisspers K. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) // BMJ. – 2013; 346: f3306.
  26. Roggeri A., Micheletto C., Roggeri D. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study // Int. J. Chron. Obstruct. Pulmon. Dis. – 2014; 9: 569–76.
  27. Suissa S., Patenaude V., Lapi F. et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia // Thorax. – 2013; 68 (11): 1029–36.
  28. Latorre M., Novelli F., Vagaggini B. et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS // Pulm. Pharmacol. Ther. – 2015; 30: 44–50.
  29. Kern D., Davis J., Williams S. et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study // Respir. Res. – 2015; 16: 52.
  30. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Inhaled_corticosteroids_for_chronic_obstructive_pulmonary_disease/human_referral_prac_000050.jsp&mid=WC0b01ac05805c516f (27.01.2017)
  31. O'Byrne P., Pedersen S., Carlsson L. et al. Risks of pneumonia in asthmatic patients taking inhaled corticosteroids // Am. J. Respir. Crit. Care Med. – 2011; 183 (5): 589–895.
  32. Mapel D., Schum M., Yood M. et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators // Prim. Care. Respir. J. – 2010; 19 (2): 109–17.
  33. Marzoratti L., Iannella H., Waterer G. Inhaled corticosteroids and the increased risk of pneumonia // Ther. Adv. Respi. Dis. – 2013; 7 (4): 225–34.
  34. Festic E., Bansal V., Gajic O. et al. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study // Mayo Clin. Proc. – 2014; 89 (2): 154–62.
  35. Yamanashi K., Marumo S., Shoji T. et al. The relationship between perioperative administration of inhaled corticosteroid and postoperative respiratory complications after pulmonary resection for non-small-cell lung cancer in patients with chronic obstructive pulmonary disease // Gen. Thorac. Cardiovasc. Surg. – 2015; 63 (12): 652–9.
  36. Ernst P., Coulombe J., Brassard P. et al. The risk of sepsis with inhaled and oral corticosteroids in patients with COPD // COPD. – 2016; 1–6. DOI: 10.1080/15412555.2016.1238450. Epub ahead of print.
  37. Vestbo J., Leather D., Diar Bakerly N. et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice // N. Engl. J. Med. – 2016; 375 (13): 1253–60.
  38. Malo de Molina R., Mortensen E., Restrepo M. et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia // Eur. Respir. J. – 2010; 36 (4): 751–7.
  39. Chen D., Restrepo M., Fine M. et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia // Am. J. Respir. Crit. Care Med. – 2011; 184 (3): 312–6.
  40. Mangi A., Bansal V., Li G. et al. Pre-hospital use of inhaled corticosteroids and inhaled beta agonists and incidence of ARDS: A population-based study // Acta Med. Acad. – 2015; 44 (2): 109–16.
  41. Sellares J., López-Giraldo A., Lucena C. et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia // Am. J. Respir. Crit. Care. Med. – 2013; 187 (11): 1241–8.
  42. Festic E., Scanlon P. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? // Am. J. Respir. Crit. Care. Med. – 2015; 191 (2): 141–8.
  43. Papi A., Jones P., Dalvi P. et al. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD // Int. J. Chron. Obstruct. Pulmon. Dis. – 2015; 10: 2431–8.